DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that five abstracts have been accepted for e-Poster ...

Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, ...

Châtillon, France, October 18, 2024 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage ...

Asthma & Immunology’s (ACAAI) 2024 Annual Scientific Meeting, held in Boston from October 24-28, 2024. The company plans to present data up to 9 months from the ongoing Phase 1 clinical trial of ...

In anticipation of the 2024 ACAAI Annual Scientific Meeting, Ruchi Gupta, MD, highlights advances in food allergy and gastrointestinal disorder management. This year, Dr Gupta is particularly ...

Pulsar International, a leading provider of managed satellite communications solutions for maritime digitalization, remote and business continuity ...

BioCryst Pharmaceuticals' upcoming presentations at the ACAAI Annual Scientific Meeting align with the company's recent financial performance and market position. According to InvestingPro data ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help tech journalists and consumers stay on top of the week's most newsworthy ...

Dr Gupta previews the 2024 ACAAI Annual Scientific Meeting, where she is anticipating updates on the first FDA-approved biologic therapy for food allergies, along with other advancements in ...

ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary ...